drugset / Trial / NCT02126956

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

NCT02126956

Phase 1 Completed 6 enrolled Actelion
NaSingle-groupOpen-label

Summary

The study was conducted to investigate the metabolism and mass balance of ACT-128800, and to identify the elimination pathways (metabolism and excretion) of ACT-128800 and compare them with the known metabolic profiles of ACT-128800 in animals.

Timeline

Start
2009-03
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule 40 mg Oral

Indications

No indication recorded.